Search research articles
Contact Us
Filters
Showing results (21-30 of 43) with videos related to
Page
of 5
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 1, 2003
High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial
Harry C Schouten, Wendi Qian, Stein Kvaloy, et al.
Blood
|
August 10, 2017
KIT signaling is dispensable for human mast cell progenitor development
Joakim S Dahlin, Maria Ekoff, Jennine Grootens, et al.
Leukemia & Lymphoma
|
January 19, 2008
Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: a randomized phase II study from the Nordic Lymphoma Group
Eva Kimby, Jesper Jurlander, Christian Geisler, et al.
Clinical Sarcoma Research
|
December 9, 2020
Preoperative accelerated radiotherapy combined with chemotherapy in a defined cohort of patients with high risk soft tissue sarcoma: a Scandinavian Sarcoma Group study
Kirsten Sundby Hall, Øyvind S Bruland, Bodil Bjerkehagen, et al.
Leukemia & Lymphoma
|
February 18, 2015
Two courses of four weekly infusions of rituximab with or without interferon-α2a: final results from a randomized phase III study in symptomatic indolent B-cell lymphomas
Eva Kimby, Björn Östenstad, Peter Brown, et al.
Haematologica
|
December 7, 2014
Successful change of treatment strategy in elderly patients with primary central nervous system lymphoma by de-escalating induction and introducing temozolomide maintenance: results from a phase II study by the Nordic Lymphoma Group
Elisa J Pulczynski, Outi Kuittinen, Martin Erlanson, et al.
Acta Oncologica (Stockholm, Sweden)
|
January 30, 2016
Malignancies in transplanted patients: Multidisciplinary evaluation and switch to mTOR inhibitors after kidney transplantation - experiences from a prospective, clinical, observational study
Vivan C Hellström, Ylva Enström, Bengt von Zur-Mühlen, et al.
The Oncologist
|
October 10, 2013
A randomized study of interferon α-2b versus no treatment as consolidation after high dose therapy and autologous stem cell transplantation for patients with relapsed lymphoma
André Bosly, Andrew Grigg, Harald Holte, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 28, 2010
Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era
Christian Gisselbrecht, Bertram Glass, Nicolas Mounier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 5, 2018
Chemotherapy-Free Initial Treatment of Advanced Indolent Lymphoma Has Durable Effect With Low Toxicity: Results From Two Nordic Lymphoma Group Trials With More Than 10 Years of Follow-Up
Sandra Lockmer, Bjørn Østenstad, Hans Hagberg, et al.
Page
of 5
Search research articles
Search
Showing results (21-30 of 43) with videos related to
Sort By:
Page
of 5
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 1, 2003
High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial
Harry C Schouten, Wendi Qian, Stein Kvaloy, et al.
Blood
|
August 10, 2017
KIT signaling is dispensable for human mast cell progenitor development
Joakim S Dahlin, Maria Ekoff, Jennine Grootens, et al.
Leukemia & Lymphoma
|
January 19, 2008
Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: a randomized phase II study from the Nordic Lymphoma Group
Eva Kimby, Jesper Jurlander, Christian Geisler, et al.
Clinical Sarcoma Research
|
December 9, 2020
Preoperative accelerated radiotherapy combined with chemotherapy in a defined cohort of patients with high risk soft tissue sarcoma: a Scandinavian Sarcoma Group study
Kirsten Sundby Hall, Øyvind S Bruland, Bodil Bjerkehagen, et al.
Leukemia & Lymphoma
|
February 18, 2015
Two courses of four weekly infusions of rituximab with or without interferon-α2a: final results from a randomized phase III study in symptomatic indolent B-cell lymphomas
Eva Kimby, Björn Östenstad, Peter Brown, et al.
Haematologica
|
December 7, 2014
Successful change of treatment strategy in elderly patients with primary central nervous system lymphoma by de-escalating induction and introducing temozolomide maintenance: results from a phase II study by the Nordic Lymphoma Group
Elisa J Pulczynski, Outi Kuittinen, Martin Erlanson, et al.
Acta Oncologica (Stockholm, Sweden)
|
January 30, 2016
Malignancies in transplanted patients: Multidisciplinary evaluation and switch to mTOR inhibitors after kidney transplantation - experiences from a prospective, clinical, observational study
Vivan C Hellström, Ylva Enström, Bengt von Zur-Mühlen, et al.
The Oncologist
|
October 10, 2013
A randomized study of interferon α-2b versus no treatment as consolidation after high dose therapy and autologous stem cell transplantation for patients with relapsed lymphoma
André Bosly, Andrew Grigg, Harald Holte, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 28, 2010
Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era
Christian Gisselbrecht, Bertram Glass, Nicolas Mounier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 5, 2018
Chemotherapy-Free Initial Treatment of Advanced Indolent Lymphoma Has Durable Effect With Low Toxicity: Results From Two Nordic Lymphoma Group Trials With More Than 10 Years of Follow-Up
Sandra Lockmer, Bjørn Østenstad, Hans Hagberg, et al.
Page
of 5